Armata Pharmaceuticals (ARMP) Current Deferred Revenue (2016 - 2017)
Armata Pharmaceuticals (ARMP) has disclosed Current Deferred Revenue for 5 consecutive years, with $20000.0 as the latest value for Q3 2017.
- Quarterly Current Deferred Revenue rose 11.11% to $20000.0 in Q3 2017 from the year-ago period, while the trailing twelve-month figure was $20000.0 through Sep 2017, up 11.11% year-over-year, with the annual reading at $245000.0 for FY2015, 0.41% changed from the prior year.
- Current Deferred Revenue hit $20000.0 in Q3 2017 for Armata Pharmaceuticals, down from $58000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $350000.0 in Q2 2015 to a low of $18000.0 in Q3 2016.
- Historically, Current Deferred Revenue has averaged $171600.0 across 5 years, with a median of $142000.0 in 2015.
- Biggest five-year swings in Current Deferred Revenue: tumbled 92.71% in 2016 and later surged 34.88% in 2017.
- Year by year, Current Deferred Revenue stood at $244000.0 in 2013, then changed by 0.0% to $244000.0 in 2014, then rose by 0.41% to $245000.0 in 2015, then crashed by 92.65% to $18000.0 in 2016, then rose by 11.11% to $20000.0 in 2017.
- Business Quant data shows Current Deferred Revenue for ARMP at $20000.0 in Q3 2017, $58000.0 in Q2 2017, and $86000.0 in Q1 2017.